Su Yudong, Meng Zhaoting, Xu Xiaoyan, Wang XinYue, Zuo Ran, Hou Yunxia, Li Kai, Chen Peng
Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin 300060, China.
Zhongguo Fei Ai Za Zhi. 2018 May 20;21(5):428-430. doi: 10.3779/j.issn.1009-3419.2018.05.13.
In recent years, the number of advanced non-small cell lung cancer (NSCLC) patients has gradually increased, and the treatment methods have also been significantly increased. However, there are no standard treatment plans at home and abroad for third-line and above patients who are refractory to targeted therapy epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) or chemotherapy. The clinical treatment effect is also not satisfactory. Anlotinib is a novel TKI targeting the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR) and c-Kit. ALTER0303 trail, phase III study has demonstrated that Anlotinib significantly prolonged overall survival (OS) and progression-free survival (PFS) in advanced NSCLC patients as 3rd line treatment.Here we report a case of advanced lung adenocarcinoma harboring KRAS mutation treated with Anlotinib. .
近年来，晚期非小细胞肺癌（NSCLC）患者数量逐渐增加，治疗方法也显著增多。然而，对于表皮生长因子受体（EGFR）/间变性淋巴瘤激酶（ALK）靶向治疗或化疗耐药的三线及以上患者，国内外尚无标准治疗方案，临床治疗效果也不尽人意。安罗替尼是一种新型酪氨酸激酶抑制剂（TKI），靶向血管内皮生长因子受体（VEGFR）、成纤维细胞生长因子受体（FGFR）、血小板衍生生长因子受体（PDGFR）和c-Kit。ALTER0303试验，一项III期研究表明，安罗替尼作为三线治疗可显著延长晚期NSCLC患者的总生存期（OS）和无进展生存期（PFS）。在此，我们报告一例接受安罗替尼治疗的KRAS突变型晚期肺腺癌病例。
